Erin R. Okawa, MD
Accepting new patients

Erin R. Okawa, MD

  • Pediatric Endocrinology
Manhattan Beach Pediatrics | 1000 North Sepulveda Boulevard, Suite 190, Manhattan Beach, CA 90266


Dr. Okawa is a Health Sciences Clinical Assistant Professor at the David Geffen School of Medicine at UCLA; she is also the Director of the Hyperinsulinism Program. She received B.A. degrees in both biology and communication at the University of Pennsylvania in Philadelphia. She then received her M.D. degree from the Sidney Kimmel Medical College (formerly Jefferson Medical College), also in Philadelphia. She completed her residency in Pediatrics at Kaiser Permanente Los Angeles Medical Center and her fellowship in Pediatric Endocrinology at Harvard-affiliated Boston Children's Hospital and the Joslin Diabetes Center. Her clinical interests include type 1 diabetes, monogenic diabetes, and hyperinsulinism.

Link to Dr. Okawa's CV >




Medical Board Certifications

Pediatric Endocrinology, American Board of Pediatrics, 2017
Pediatrics, American Board of Pediatrics, 2014


Pediatric Endocrinology, Boston Children's Hospital, Harvard Medical School, 2017


Pediatrics, Kaiser Permanente - Los Angeles Medical Center, 2014


MD, Jefferson Medical College of Thomas Jefferson University, 2011


Hospital Affiliations

Medical Services



  1. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM. Definition and characterization of a region of 1p36.6 consistently deleted in neuroblastoma. Oncogene, 2005, 24(16):2684-94.
  2. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung N, Gerald W, London W, Matthay K, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Research, 2006, 66(12):6050-62.
  3. Okawa ER, Gotoh T, Igarashi J, Fujita T, Manne J, Silverman KA, Mosse Y, White PS, Brodeur GM. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene, 2008, 27(6):803-10.
  4. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kim J, Zhao H, Pawel B, Maris JM, White PS, Brodeur GM. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute, 2008, 100(13):940-9.
  5. Okawa ER, Grant FD, Smith JR. Pediatric Graves' disease: decisions regarding therapy. Current Opinions in Pediatrics, 2015, 27(4):442-7.
  6. Naraparaju K, Kolla V, Zhuang T, Higashi M, Iyer R, Kolla S, Okawa ER, Blobel GA, Brodeur GM. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor. Oncotarget, 2016, 7(13):15977-85.
  7. Kahraman S, Okawa ER, Kulkarni RN. Is transforming stem cells to pancreatic beta cells the holy grail for type 2 diabetes? Current Diabetes Reports, 2016, 16(8):70.
  8. Shirakawa J, Fernandez M, Takatani T, El Ouaamari A, Jungtrakoon P, Okawa ER, Zhang W, Yi P, Doria A, Kulkarni Insulin signaling regulates the FoxM1/PLK1/CEN-PA pathway to promote beta cell proliferation. Cell Metabolism, 2017, 25(4):868-882.e5.
  9. Weng CH, Okawa ER, Roberts MB, Park SK, Umbricht CB, Manson JE, Eaton CB. Breast cancer risk in postmenopausal women with medical history of thyroid disorder in the Women's Health Initiative. Thyroid, 2020, 30(4): 519-530.

Link to Dr. Okawa's CV >


  • Aetna
  • Anthem Blue Cross
  • Blue Shield of California
  • Centivo
  • Cigna
  • First Health
  • Health Net of California
  • Interplan (part of HealthSmart)
  • L.A. Care
  • MultiPlan
  • UFCM Health System
  • Prime Health Services
  • Private Healthcare Systems (PHCS)
  • UnitedHealthcare

The list of health care plans above may not be comprehensive and could change. 
Please contact your benefits coordinator or health insurance company directly to verify coverage.

Visit our health insurance information page for more details.